Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caribou Biosciences Inc (CRBU)

Caribou Biosciences Inc (CRBU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 146,745
  • Shares Outstanding, K 93,468
  • Annual Sales, $ 9,990 K
  • Annual Income, $ -149,110 K
  • EBIT $ -159 M
  • EBITDA $ -160 M
  • 60-Month Beta 2.61
  • Price/Sales 15.73
  • Price/Cash Flow N/A
  • Price/Book 1.07

Options Overview Details

View History
  • Implied Volatility 377.88% (+114.13%)
  • Historical Volatility 70.94%
  • IV Percentile 97%
  • IV Rank 75.26%
  • IV High 471.92% on 05/21/25
  • IV Low 91.77% on 07/18/25
  • Expected Move (DTE 9) 0.5525 (34.75%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 197
  • Volume Avg (30-Day) 147
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 5,823
  • Open Int (30-Day) 6,988
  • Expected Range 1.0375 to 2.1425

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.33
  • Number of Estimates 5
  • High Estimate -0.30
  • Low Estimate -0.35
  • Prior Year -0.39
  • Growth Rate Est. (year over year) +15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3800 +15.22%
on 02/02/26
1.7400 -8.62%
on 02/03/26
-0.0700 (-4.22%)
since 01/09/26
3-Month
1.3800 +15.22%
on 02/02/26
2.3000 -30.87%
on 11/13/25
-0.6500 (-29.02%)
since 11/11/25
52-Week
0.6600 +140.91%
on 04/07/25
3.5400 -55.08%
on 11/03/25
+0.3300 (+26.19%)
since 02/11/25

Most Recent Stories

More News
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical...

CRBU : 1.5900 (+1.27%)
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting ...

CRBU : 1.5900 (+1.27%)
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Vispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class...

CRBU : 1.5900 (+1.27%)
Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will...

CRBU : 1.5900 (+1.27%)
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-term...

CRBU : 1.5900 (+1.27%)
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma 450 million cell dose is the recommended...

CRBU : 1.5900 (+1.27%)
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold...

CRBU : 1.5900 (+1.27%)
Bank of America Securities Sticks to Their Buy Rating for Caribou Biosciences (CRBU)

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Caribou Biosciences today. The company’s shares closed yesterday at $2.26.Elevate Your Investing Strategy: Take advantage...

CRBU : 1.5900 (+1.27%)
Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,...

CRBU : 1.5900 (+1.27%)
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in  H2 2025 -- -- $184 million in cash, cash equivalents, and marketable securities expected to fund the Company’s...

CRBU : 1.5900 (+1.27%)

Business Summary

Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 1.7600
2nd Resistance Point 1.6800
1st Resistance Point 1.6350
Last Price 1.5900
1st Support Level 1.5100
2nd Support Level 1.4300
3rd Support Level 1.3850

See More

52-Week High 3.5400
Fibonacci 61.8% 2.4398
Fibonacci 50% 2.1000
Fibonacci 38.2% 1.7602
Last Price 1.5900
52-Week Low 0.6600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar